UBS Group’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,356,812
| Closed | -$170M | – | 11064 |
|
|
2025
Q4 | $170M | Buy |
2,356,812
+1,040,953
| +79% | +$67.2M | 0.03% | 664 |
|
|
2025
Q3 | $57.3M | Buy |
1,315,859
+719,305
| +121% | +$29.1M | 0.01% | 1490 |
|
|
2025
Q2 | $16.9M | Sell |
596,554
-1,441
| -0.2% | -$43K | ﹤0.01% | 2546 |
|
|
2025
Q1 | $17.7M | Buy |
597,995
+392,089
| +190% | +$12.2M | ﹤0.01% | 2463 |
|
|
2024
Q4 | $5.99M | Buy |
205,906
+28,030
| +16% | +$1.17M | ﹤0.01% | 3620 |
|
|
2024
Q3 | $8.17M | Buy |
177,876
+73,493
| +70% | +$3.19M | ﹤0.01% | 2561 |
|
|
2024
Q2 | $4.26M | Sell |
104,383
-91,063
| -47% | -$2.61M | ﹤0.01% | 3022 |
|
|
2024
Q1 | $4.99M | Buy |
195,446
+1,095
| +0.6% | +$17.2K | ﹤0.01% | 2978 |
|
|
2023
Q4 | $1.76M | Buy |
194,351
+78,387
| +68% | +$524K | ﹤0.01% | 3964 |
|
|
2023
Q3 | $740K | Sell |
115,964
-67,102
| -37% | -$578K | ﹤0.01% | 4353 |
|
|
2023
Q2 | $2.03M | Buy |
183,066
+101,832
| +125% | +$1.28M | ﹤0.01% | 3507 |
|
|
2023
Q1 | $1.25M | Sell |
81,234
-83,754
| -51% | -$1.84M | ﹤0.01% | 3903 |
|
|
2022
Q4 | $3.66M | Buy |
164,988
+137,167
| +493% | +$2.05M | ﹤0.01% | 2797 |
|
|
2022
Q3 | $455K | Sell |
27,821
-13,258
| -32% | -$254K | ﹤0.01% | 4418 |
|
|
2022
Q2 | $597K | Sell |
41,079
-49,787
| -55% | -$741K | ﹤0.01% | 4130 |
|
|
2022
Q1 | $1.68M | Buy |
90,866
+8,638
| +11% | +$147K | ﹤0.01% | 3604 |
|
|
2021
Q4 | $1.96M | Buy |
82,228
+44,542
| +118% | +$1.06M | ﹤0.01% | 3756 |
|
|
2021
Q3 | $928K | Buy |
37,686
+33,866
| +887% | +$736K | ﹤0.01% | 4253 |
|
|
2021
Q2 | $94K | Sell |
3,820
-27,056
| -88% | -$629K | ﹤0.01% | 5932 |
|
|
2021
Q1 | $673K | Buy |
30,876
+28,979
| +1,528% | +$709K | ﹤0.01% | 4626 |
|
|
2020
Q4 | $49K | Buy |
+1,897
| New | +$55.3K | ﹤0.01% | 6205 |
|
Other funds holding RNAM
UBS Group's RNAM Position: Q1 2026 in Review
UBS Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 2,356,812 shares — an estimated $170M sold.
UBS Group first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $170M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- UBS Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 2,356,812 Avidity Biosciences shares in Q1 2026, an estimated $170M.
- UBS Group first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
- UBS Group's Avidity Biosciences position peaked at $170M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.